Search
TM5614
go.drugbank.com/drugs/DB16516InvestigationalAn animal study in mice fed a fast-food diet with TM5614 treatment showed improved metabolic measurements and reduced liver steatosis[L31673,L31678]. … Further investigation of this compound is underway, including an exploratry Phase II study for its efficacy and safety for high-risk hospitalized patients with severe COVID-19 pneumonia[L31688].
SR 121463
go.drugbank.com/drugs/DB05455InvestigationalIt is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Lovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigational[A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … [L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients
PF-05212377
go.drugbank.com/drugs/DB16044Investigationalon Donepezil). … PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms
Apadenoson
go.drugbank.com/drugs/DB05009InvestigationalIt is developed by Bristol-Myers Squibb and is in phase II of clinical trials. … Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.
Apatorsen
go.drugbank.com/drugs/DB06094InvestigationalApatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers
AVAC
go.drugbank.com/drugs/DB05441ExperimentalIt has been tested in uses related to asthma and in treating eczema and atopic dermatitis.
YKP-1358
go.drugbank.com/drugs/DB06109ExperimentalIn addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects. … YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.
Candida albicans
go.drugbank.com/drugs/DB10429ApprovedInvestigationalCandida albicans is used in allergenic testing.